Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

  • STATUS
    Recruiting
  • End date
    Jun 23, 2024
  • participants needed
    120
  • sponsor
    Nordic Lymphoma Group
Updated on 23 January 2021
burkitt's lymphoma
follicular lymphoma
b-cell lymphoma
t-cell lymphoma
large cell lymphoma
chemoimmunotherapy
da-epoch
transformed lymphoma

Summary

This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).

Description

For young clinically high-risk diffuse large B-cell lymphoma (DLBCL) patients the optimal therapy has not been established. Previous Nordic phase II studies, where dose-dense chemoimmunotherapy (R-CHOEP-14) with systemic CNS prophylaxis (HD-Mtx and HD-AraC) was given, demonstrated favorable outcome in comparison to historical controls. However, the patients with biological risk factors, such as translocation of bcl2 and myc oncogenes or and/or high BCL2 and MYC expression or deletion 17p and/or high P53 expression had significantly higher risk of death, as compared to patients without aberrations. The figures provide evidence for an unmet clinical need for the patients with biological risk factors, and underscore the importance of a clinical trial, where both biological and clinical risk factors play a role in the treatment planning.

In this trial treatment intensity varies according to presence or absence of biological risk factors. All patients receive a prephase medication consisting of prednisone and vincristine and two cycles of R-CHOP and high dose (HD) methotrexate. Subsequently, depending on the biological risk factors either four additional cycles of R-CHOEP (standard arm with no risk factors) or four dose adjusted R-EPOCH courses (experimental arm with risk factors) are given, followed by one course of high dose cytarabine (Ara-C) and R. R-CHOEP courses should be given with a two-week and R-EPOCH with a three-week interval.

Details
Condition Diffuse Large B-Cell Lymphoma
Treatment DA-EPOCH-R, R-CHOEP
Clinical Study IdentifierNCT03293173
SponsorNordic Lymphoma Group
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 64 yrs?
Gender: Male or Female
Do you have Diffuse Large B-Cell Lymphoma?
Do you have any of these conditions: Do you have Diffuse Large B-Cell Lymphoma??
Age 18 - 64 years
Histologically confirmed CD20+ DLBCL based on revised WHO 2008 Lymphoma Classification. The following subgroups and variants can be included
ALK-positive large B-cell lymphoma
Intravascular large B-cell lymphoma
T-cell rich B-cell lymphoma
Myc/BCL-2 double hit lymphoma
Follicular lymphomas grade 3b
DLBCL with previously undiagnosed concurrent small cell infiltration in bone marrow, lymph node, or extranodal site and lymphomas intermediate between DLBCL and Burkitt's lymphoma are allowed
Posttransplantation lymphoma (PTLD), discordant or transformed lymphoma are NOT allowed
Patients in at least stage II with age adjusted IPI score of 2 or 3
Stage III /IV and elevated LDH
Stage III/IV and WHO performance status 2 - 3
Stage II and elevated LDH and WHO performance status 2 - 3
And/or patients with site specific risk factors for CNS recurrence defined as follows
More than one extranodal site
Testicular lymphoma, stage IIE and higher
Paranasal sinus and orbital lymphoma with destruction of bone
Large cell lymphoma infiltration of the bone marrow
Previously untreated, except steroids allowed
WHO performance status 0-3
Written informed consent

Exclusion Criteria

Severe cardiac disease: cardiac function grade 3-4, left ventricular ejection fraction <45%
Impaired bone marrow liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule (Hemoglobin < 9 g/dL, ANC < 1.5 109/L, Platelet count < 75 109/L, creatinine clearance < 40 mL/min, ALT/AST > 2.5 x ULN, bilirubin 1.5 x ULN, INR > 1.5)
Pregnancy/lactation
Men and women of reproductive potential not agreeing to use effective contraception during treatment and for 18 months after completion of treatment (Effective contraception is combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), hormone-releasing IUD, bilateral tubal occlusion, vasectomised partner, or sexual abstinence
Patients with other severe medical problems, including active infections, cardiac or pulmonary disease, history of PML and with an expected short survival for non-lymphoma reasons
Known HIV positivity
Active or chronic hepatitis B virus (HBV) infection (defined as positive HBsAg serology), or active hepatitis C virus (HCV) infection (defined by antibody serology testing). HBsAg, HBcAb, and HCVAb must be tested during screening. Patients who have protective titers of HBsAb along negative HBsAg after vaccination or prior but cured hepatitis B are eligible
Vaccination with a live vaccine within one month prior to randomization
Patients with a malignancy that has been treated but not with curative intent, unless the malignancy has been in remission without treatment for 5 years prior to enrollment
Earlier treatment containing anthracyclines
Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol
CNS disease as diagnosed by MRI or CSF cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed
Transformed lymphoma
Primary mediastinal B-cell lymphoma
Pleural or peritoneal fluid that cannot be drained safely
Hypersensitivity to the active substance or any of the other ingredients
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
Patients participating in other clinical studies, unless followed for survival
Lower urinary tract constriction, which cannot be treated adequately
Degenerative and toxic encephalopathy
Neuromuscular disease
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note